ELZONRIS (tagraxofusp)

MEDICAL BENEFIT - INTRAVENOUS ADMINISTRATION 

Indications for Prior Authorization:

  • Indicated in adults and pediatric patients ≥ 2 years of age for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Patients must meet the following criteria for the indication(s) above:

  • Patient is ≥ 2 years of age, AND
  • Diagnosis of BPDCN confirmed by chart note documentation, AND
  • Prescribed by or in consultation with an oncologist or hematologist

Dosing:

  • IV: 12 mcg/kg over 15 minutes once daily on days 1 to 5 of a 21-day cycle
  • Prior to first dose, ensure that the serum albumin level is ≥ 3.2 g/dL
  • Dosing period may be extended for dose delays up to day 10 of the cycle
  • Consider pre-treatment with histamine-1 antagonist, histamine-2 antagonist, a corticosteroid, and acetaminophen approximately 1 hour prior to administering Elzonris™

Approval:

  • 1 year

Last review date: May 21, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone